WHO ICTRP trial
A clinical research study to evaluate the safety and tolerability of a topically…
ISRCTN78313275 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN78313275 |
|---|---|
| Public title | A clinical research study to evaluate the safety and tolerability of a topically applied investigational drug product in adults with vitiligo and to evaluate if it helps in restoring the pigment/color to the affected skin |
| Scientific title | A phase Ib/IIa, proof of concept, double-blind, placebo-controlled, intraindividual randomized study to evaluate the safety, tolerability, and preliminary efficacy of VIM-004 gel in participants with vitiligo |
| Primary sponsor | Vimela Therapeutics, Ltd. |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase I/II |
| Countries | Mauritius |
| Conditions | Vitiligo Skin and Connective Tissue Diseases |
| Interventions | All eligible participants will be randomized using the randomization list provided by an unblinded statistician. The randomization list will define the treatment (VIM-004 Gel or VIM-004 Placebo Gel) to be allocated to each treatment area… |
| Registration date | Oct 30, 2024 |
| Target size | 25 |
| Secondary IDs | Nil known;Nil known;VIM-004 Gel-01/ 2324CMPH078 |
| Registry page | isrctn.com |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: